C.Diff Unmet Need Overcomes Bezlotoxumab Panel's Efficacy Concerns
Advisory committee votes 10-5 for approval of the monoclonal antibody for prevention of C. difficile recurrence; drug shows 10% absolute reduction in recurrence vs. placebo.
Advisory committee votes 10-5 for approval of the monoclonal antibody for prevention of C. difficile recurrence; drug shows 10% absolute reduction in recurrence vs. placebo.